SARS-CoV-2刺突蛋白直接激活补体替代途径且被因子D抑制阻断
该研究探讨SARS-CoV-2刺突蛋白是否直接激活补体替代途径。结果显示刺突蛋白(S1和S2亚基)而非N蛋白直接激活替代途径,C5或因子D抑制可阻断补体依赖性杀伤,因子D抑制同时阻止C3c和C5b-9沉积,C5抑制仅阻止C5b-9蓄积。
要点
- SARS-CoV-2刺突蛋白(S1和S2亚基)而非N蛋白直接激活补体替代途径。
- 因子D抑制可同时阻止C3c和C5b-9在细胞表面蓄积。
- C5抑制仅阻止C5b-9蓄积,不阻止上游补体激活。
核心结论
- SARS-CoV-2刺突蛋白通过阻止细胞表面替代途径C3转化酶灭活,将非激活表面转化为激活表面。
- 替代途径激活可能解释COVID-19中观察到的微血管病、血小板减少、肾损伤和血栓倾向等临床表现。
研究设计与样本
- 体外实验研究,使用修饰Ham试验检测补体依赖性杀伤,TF1PIGAnull靶细胞及刺突蛋白处理细胞上清液。
主要发现
- 刺突蛋白(S1和S2亚基)而非N蛋白直接激活补体替代途径。
- 修饰Ham试验中补体依赖性杀伤可被C5抑制或因子D抑制阻断。
- 刺突蛋白处理细胞上清液中补体因子Bb升高,C3片段和C5b-9沉积于TF1PIGAnull靶细胞。
- C5抑制阻止C5b-9在细胞上蓄积但不阻止C3c蓄积;因子D抑制同时阻止C3c和C5b-9蓄积。
- 加入因子H可减轻补体攻击。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious respiratory virus that can lead to venous/arterial thrombosis, stroke, renal failure, myocardial infarction, thrombocytopenia, and other end-organ damage. Animal models demonstrating end-organ protection in C3-deficient mice and evidence of complement activation in humans have led to the hypothesis that SARS-CoV-2 triggers complement-mediated endothelial damage, but the mechanism is unclear. Here, we demonstrate that the SARS-CoV-2 spike protein (subunit 1 and 2), but not the N protein, directly activates the alternative pathway of complement (APC). Complement-dependent killing using the modified Ham test is blocked by either C5 or factor D inhibition. C3 fragments and C5b-9 are deposited on TF1PIGAnull target cells, and complement factor Bb is increased in the supernatant from spike protein-treated cells. C5 inhibition prevents the accumulation of C5b-9 on cells, but not C3c; however, factor D inhibition prevents both C3c and C5b-9 accumulation. Addition of factor H mitigates the complement attack. In conclusion, SARS-CoV-2 spike proteins convert nonactivator surfaces to activator surfaces by preventing the inactivation of the cell-surface APC convertase. APC activation may explain many of the clinical manifestations (microangiopathy, thrombocytopenia, renal injury, and thrombophilia) of COVID-19 that are also observed in other complement-driven diseases such as atypical hemolytic uremic syndrome and catastrophic antiphospholipid antibody syndrome. C5 inhibition prevents accumulation of C5b-9 in vitro but does not prevent upstream complement activation in response to SARS-CoV-2 spike proteins.
引用
- Yu J, Yuan X, Chen H, et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020. PMID: 32877502. doi:10.1182/blood.2020008248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。